Profile data is unavailable for this security.
About the company
Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.
- Revenue in JPY (TTM)72.62m
- Net income in JPY-905.42m
- Incorporated2001
- Employees17.00
- LocationKringle Pharma Inc207Saito Bio Incubator, 7-7-15, SaitoasagiIBARAKI-SHI 567-0085JapanJPN
- Phone+81 726418739
- Fax+81 726418730
- Websitehttps://www.kringle-pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PhoenixBio Co Ltd | 1.51bn | -311.88m | 1.97bn | 69.00 | -- | 1.42 | -- | 1.30 | -78.53 | -78.53 | 372.28 | 339.41 | 0.6513 | 0.9529 | 6.96 | 21,877,380.00 | -13.46 | -4.25 | -16.43 | -5.57 | 75.84 | 67.17 | -20.66 | -7.19 | 2.91 | -- | 0.2067 | -- | -10.14 | 3.29 | -1,801.92 | -- | 1.08 | -- |
| Kringle Pharma Inc | 72.62m | -905.42m | 2.98bn | 17.00 | -- | 2.37 | -- | 40.98 | -130.95 | -130.95 | 10.48 | 170.57 | 0.032 | -- | 1.01 | 4,272,000.00 | -39.93 | -23.52 | -42.03 | -24.93 | -- | -- | -1,246.73 | -349.89 | 16.65 | -3,738.20 | 0.00 | -- | -9.77 | -31.17 | -21.13 | -- | -- | -- |
| Veritas In Silico Inc | 91.14m | -425.67m | 3.11bn | 19.00 | -- | 1.75 | -- | 34.17 | -65.62 | -65.62 | 14.05 | 274.99 | 0.0441 | -- | 6.11 | -- | -20.59 | -- | -21.32 | -- | -- | -- | -467.05 | -- | 18.35 | -- | -- | -- | -53.18 | -- | -80.03 | -- | -- | -- |
| NPT Co Ltd | 0.00 | -266.47m | 3.41bn | 7.00 | -- | 43.82 | -- | -- | -54.98 | -54.98 | 0.00 | 15.98 | 0.00 | -- | -- | 0.00 | -318.44 | -- | -439.04 | -- | -- | -- | -- | -- | -- | -2,152.88 | 0.00 | -- | -- | -- | -68.67 | -- | -- | -- |
| FunPep Co Ltd | 314.00k | -1.91bn | 3.98bn | 15.00 | -- | 2.72 | -- | 12,660.04 | -51.03 | -51.03 | 0.0083 | 36.09 | 0.0001 | -- | -- | -- | -75.09 | -37.74 | -92.91 | -41.17 | -- | -- | -608,766.90 | -4,142.72 | 3.71 | -- | -- | -- | -94.88 | -36.20 | -115.00 | -- | -- | -- |
| Human Metabolome Technologies Inc | 1.43bn | 207.06m | 4.12bn | 62.00 | 19.65 | -- | 27.54 | 2.88 | 35.42 | 35.42 | 248.83 | -- | 0.6237 | 10.29 | 4.91 | 23,060,290.00 | 9.03 | 10.54 | 10.98 | 13.59 | 60.48 | 66.65 | 14.48 | 17.24 | 5.13 | 391.35 | 0.0555 | 20.98 | 8.12 | 5.40 | 5.42 | -- | 33.68 | -- |
| Ribomic Inc | 0.00 | -1.05bn | 4.67bn | 25.00 | -- | 1.36 | -- | -- | -23.81 | -23.81 | 0.00 | 63.04 | 0.00 | -- | -- | 0.00 | -31.15 | -29.95 | -32.30 | -31.15 | -- | -- | -- | -2,725.95 | 25.20 | -- | 0.00 | -- | -- | -55.55 | 0.5173 | -- | -6.86 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.06bn | 5.16bn | 14.00 | -- | 1.75 | -- | -- | -27.71 | -27.71 | 0.00 | 33.64 | 0.00 | -- | -- | 0.00 | -66.07 | -35.65 | -74.94 | -36.83 | -- | -- | -- | -1,981.18 | -- | -- | 0.0888 | -- | -- | -- | 44.90 | -- | -67.80 | -- |
| D.Western Therapeutics Institute Inc | 419.76m | -1.06bn | 5.75bn | 21.00 | -- | 3.85 | -- | 13.70 | -24.98 | -24.98 | 9.48 | 27.56 | 0.1921 | 0.4194 | 2.71 | 19,988,760.00 | -48.31 | -24.39 | -52.24 | -26.58 | 89.75 | 93.00 | -251.53 | -142.25 | 8.69 | -274.87 | 0.2606 | -- | 10.09 | -4.07 | -58.82 | -- | -- | -- |
| Carna Biosciences, Inc. | 579.06m | -2.17bn | 5.94bn | 63.00 | -- | 19.19 | -- | 10.25 | -113.62 | -113.62 | 30.30 | 16.16 | 0.2894 | 1.24 | 6.17 | -- | -108.53 | -37.21 | -120.28 | -41.98 | 67.03 | 86.49 | -375.00 | -118.28 | 6.08 | -75.55 | 0.6979 | -- | -8.99 | -12.57 | 0.3262 | -- | -33.02 | -- |
